Opa1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
OPA1 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of OPA1 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
OPA1 is a dynamin-related GTPase localized to the inner mitochondrial membrane that plays essential roles in:
- Mitochondrial inner membrane fusion: Mediates inner membrane fusion
- Cristae maintenance: Preserves mitochondrial cristae structure
- Mitochondrial DNA maintenance: Essential for mtDNA nucleoid organization
- Apoptosis regulation: Controls cytochrome c release
- Cellular energy metabolism: Maintains oxidative phosphorylation
- Most common inherited optic neuropathy
- Primary cause is OPA1 mutations (60-70% of cases)
- Selective degeneration of retinal ganglion cells
- Progressive vision loss
- OPA1 dysfunction contributes to mitochondrial defects in PD
- PINK1/Parkin pathway interacts with OPA1
- Mitochondrial fragmentation in dopaminergic neurons
- Mutations can cause "plus" syndromes with extra-ocular manifestations
- Hearing loss, peripheral neuropathy, ataxia (DOA+ syndrome)
- High expression in retinal ganglion cells
- Expressed in brain regions with high metabolic demand
- Hippocampus, cortex, substantia nigra
- 10853840: OPA1 mutations cause dominant optic atrophy. Nat Genet, 2000.
- 18581056: OPA1 in mitochondrial dynamics. Nat Rev Neurosci, 2008.
- 26791242: OPA1 and neurodegeneration. J Neurochem, 2016.
The study of Opa1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sun K et al.. "Mitophagy in degenerative joint diseases." Autophagy (2021). DOI: 10.1080/15548627.2020.1822097 PubMed: 32967533
- Pahlavani HA. "Exercise therapy to prevent and treat Alzheimer's disease." Frontiers in aging neuroscience (2023). DOI: 10.3389/fnagi.2023.1243869 PubMed: 37600508
- Hou Y et al.. "Rhodiola crenulata alleviates hypobaric hypoxia-induced brain injury by maintaining BBB integrity and balancing energy metabolism dysfunction." Phytomedicine (2024). DOI: 10.1016/j.phymed.2024.155529 PubMed: 38503156
- Herkenne S et al.. "Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1." Cell metabolism (2020). DOI: 10.1016/j.cmet.2020.04.007 PubMed: 32315597
- Nasoni MG et al.. "Melatonin reshapes the mitochondrial network and promotes intercellular mitochondrial transfer via tunneling nanotubes after ischemic-like injury in hippocampal HT22 cells." Journal of pineal research (2021). DOI: 10.1111/jpi.12747 PubMed: 34085316
- Choong CJ et al.. "Alternative mitochondrial quality control mediated by extracellular release." Autophagy (2021). DOI: 10.1080/15548627.2020.1848130 PubMed: 33218272
- Chang X et al.. "ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles." Redox biology (2023). DOI: 10.1016/j.redox.2023.102739 PubMed: 37187014
- Salminen A et al.. "Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome." Progress in neurobiology (2013). DOI: 10.1016/j.pneurobio.2013.06.002 PubMed: 23827971